AEYE-DS has set a new standard in diabetic retinopathy screening by demonstrating exceptional accuracy with highly portable devices, requiring minimal intervention.

A new study reveals that AEYE-DS has reached an impressive 96% success rate in diabetic eye screenings without dilation, showcasing its effectiveness in high-traffic clinics.

NEW YORK, July 31, 2025 /PRNewswire/ -- AEYE Health, the leader in AI-powered retinal diagnostics, announces the appointment of Dr. Pamela F. Gallin as its Chief Medical Officer. A highly reputable and renowned ophthalmologist, Dr. Gallin brings decades of clinical, academic, and...

In Memory of Dr. James Ledwith NEW YORK, Dec. 10, 2024 /PRNewswire/ -- AEYE Health , the leader in artificial intelligence-based diagnostics for retinal imaging, and UMass Memorial Health (UMMH), the largest not-for-profit health care system in Central…

Aim To evaluate a real-world clinical integration of an autonomous artificial intelligence (AI) system (AEYE Diagnostic Screening (AEYE-DS), AEYE Health, USA) for diabetic retinopathy (DR) screening using the Topcon NW500 camera (Topcon, Japan) in an endocrinology clinic.Methods Adults with type 1 or type 2 diabetes without previously reported DR attending routine endocrinology follow-up were invited to participate. Non-mydriatic, macula-centred fundus photographs were acquired by a novice, non-ophthalmic operator. Images were analysed by AEYE-DS to detect more-than-mild DR (mtmDR). AI-positive results prompted physician counselling and automated referral for internal confirmatory examination.Results Definitive AEYE-DS results were obtained for 95.7% (245/256) of participants without pharmacological dilation. Seventy-six (29.6%) patients screened positive for mtmDR, of whom 34 (44.7%) completed confirmatory examination at the institution’s retina clinic; externally completed follow-up was not captured. Four patients (11.8% of those evaluated) required treatment with intravitreal anti-vascular endothelial growth factor therapy or panretinal photocoagulation. Additional previously unrecognised ocular conditions were identified among several AI-positive patients. Patient satisfaction was high, with >80% reporting the screening was easy to use, time-efficient and recommendable.Conclusions In a real-world endocrinology clinic, autonomous AI screening for DR using AEYE-DS integrated with the Topcon NW500 enabled efficient DR screening and achieved high non-mydriatic imageability. A clinically relevant proportion of patients requiring ophthalmic evaluation has been captured. Internal referral for confirmatory testing enabled assessment of downstream outcomes. The findings support scalable, point-of-care autonomous screening and a stepped-referral approach for AI-positive patients.

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic partnership between AEYE Health and Ford Medical, according to a press release from AEYE. The AI-driven technology, called AEYE-DS, works with compatible retinal cameras to enable point-of-care diabetic retinopathy screening. The partnership will see Ford Medical distribute the system to pharmacies and non-acute centers in the U.S., according to the release. “This solution is fully autonomous. Unlike all other AI solutions, it doesn’t just measure or do decision

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic partnership between AEYE Health and Ford Medical, according to a press release from AEYE. The AI-driven technology, called AEYE-DS, works with compatible retinal cameras to enable point-of-care diabetic retinopathy screening. The partnership will see Ford Medical distribute the system to pharmacies and non-acute centers in the U.S., according to the release. “This solution is fully autonomous. Unlike all other AI solutions, it doesn’t just measure or do decision